Rubius Therapeutics is dropping its lead drug candidate—and its focus on rare diseases—in favor of earlier-stage cell therapies that it has been developing for oncology and autoimmune disorders. The Cambridge, MA-based company disclosed the strategy shift Thursday in its report of fourth quarter and full year 2019 financial results. After the announcement, shares of Rubius … Continue reading “Rubius Drops Rare Diseases, Turns to Cancer and Autoimmune Disorders”
Category: Boston
G1’s Demaree Jumps to Karyopharm for Chief Commercial Officer Job
John Demaree is joining Karyopharm Therapeutics (NASDAQ: [[ticker:KPTI]]) as its chief commercial officer, the same position he held most recently at G1 Therapeutics (NASDAQ: [[ticker:GTHX]]). His experience also includes positions at Astellas Pharma, Abbott Laboratories (NYSE: [[ticker:ABT]]), Novartis (NYSE: [[ticker:NVS]]), and Eli Lilly (NYSE: [[ticker:LLY]]). Newton, MA-based Karyopharm recently reported positive results from a Phase … Continue reading “G1’s Demaree Jumps to Karyopharm for Chief Commercial Officer Job”
Harbour BioMed Tacks on $75M to Advance Broad Biologics Pipeline
A biotech born out of an antibody platform company has added another $75 million to its investment haul, money it says will allow it to advance its clinical-stage compounds and continue to build its portfolio of earlier-stage therapeutics. Shanghai-based Harbour BioMed emerged in 2016 after acquiring technology developed by Harbour Antibodies, a Dutch company that … Continue reading “Harbour BioMed Tacks on $75M to Advance Broad Biologics Pipeline”
Imara Dives Into Coronavirus-Churned Financial Waters With a $75M IPO
The global economy is in tumult as the new coronavirus sparks financial contagion but drug developer Imara pressed ahead with its IPO anyway, raising $75.2 million in its stock market debut. Late Wednesday, Imara offered 4.7 million shares for $16 apiece, which was the low end of its projected price range. The Boston-based company had … Continue reading “Imara Dives Into Coronavirus-Churned Financial Waters With a $75M IPO”
Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic
Reuse and recycle is more than an environmental slogan. It’s also a succinct description of how cells deal with old or damaged proteins. Kymera Therapeutics is developing drugs that use this cyclical cellular process to treat disease, and it has raised $102 million to move into clinical testing next year. The Series C round of … Continue reading “Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic”
Acceleron Drops Drug for Rare Muscle Disease After Mixed Phase 2 Data
An experimental Acceleron Pharma drug for rare neuromuscular diseases has failed to distance itself from a placebo in a mid-stage study, spelling the end for that program. Acceleron (NASDAQ: [[ticker:XLRN]]) drug ACE-083 was being developed as a treatment for Charcot-Marie-Tooth disease, a hereditary nerve disorder that leads to the progressive loss of muscle function. The … Continue reading “Acceleron Drops Drug for Rare Muscle Disease After Mixed Phase 2 Data”
Kala to Take Another Shot at FDA Approval With New Dry Eye Drug Data
A Kala Pharmaceuticals dry eye disease drug that was rejected by the FDA is now being readied for another regulatory filing based on new data. Last August the FDA rejected a Kala (NASDAQ: [[ticker:KALA]]) product meant to temporarily relieve signs and symptoms of dry eye disease. On Monday the Watertown, MA-based biopharma announced preliminary results … Continue reading “Kala to Take Another Shot at FDA Approval With New Dry Eye Drug Data”
Cushing’s Disease Drug That Novartis Sold to Recordati Nabs FDA Nod
A Cushing’s disease drug whose rights Novartis sold to Italy-based Recordati last year now has FDA approval. Cushing’s disease is a rare disorder in which the adrenal glands make too much of a hormone called cortisol. The Novartis (NYSE: [[ticker:NVS]]) drug, osilodrostat (Isturisa), is intended to block an enzyme key to cortisol production. The FDA … Continue reading “Cushing’s Disease Drug That Novartis Sold to Recordati Nabs FDA Nod”
Zentalis Leads a Trio of Biotechs Charting a Course for Wall Street
Cell therapies and antibody drugs grab much of the attention and investment in cancer drug development but the scientists at Zentalis Pharmaceuticals contend that there’s a place for small molecules too. Now the biotech is preparing for an initial public stock offering to advance its pipeline, which includes a lead candidate in testing in combination … Continue reading “Zentalis Leads a Trio of Biotechs Charting a Course for Wall Street”
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
Last month, Gilead Sciences CEO Daniel O’Day announced plans to introduce 10 “transformative medicines” over the next 10 years. Acquisitions would help meet that ambitious goal, and this week Gilead announced one of them: a nearly $5 billion deal for cancer immunotherapy developer Forty Seven. Forty Seven’s lead CD47-blocking drug—the company is named after the … Continue reading “Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More”
AMAG Pharma Chief Medical Officer Julie Krop to Step Down
Julie Krop, chief medical officer of AMAG Pharmaceuticals (NASDAQ: [[ticker:AMAG]]) since 2015, is leaving at the end of the month, the Waltham, MA-based company announced Wednesday. Krop has agreed to provide “support and transition services” through March 31, according to a securities filing. No reason was given for Krop’s departure, but it follows the January … Continue reading “AMAG Pharma Chief Medical Officer Julie Krop to Step Down”
BlueRock Hires Former Unum Exec Ettenberg as Chief Scientific Officer
BlueRock Therapeutics has appointed Seth Ettenberg to serve as its chief scientific officer. He comes to the Cambridge, MA-based cell and gene therapy developer from Unum Therapeutics (NASDAQ: [[ticker:UNUM]]), where he was chief scientific officer from the company’s 2014 founding until a corporate restructuring earlier this week. BlueRock, which was acquired by Bayer last year … Continue reading “BlueRock Hires Former Unum Exec Ettenberg as Chief Scientific Officer”
Novartis Leads $100M Round for Fibrosis-Focused Pliant Therapeutics
When Novartis signed on as a partner to Pliant Therapeutics last fall, it also agreed to eventually take an equity stake in the smaller biotech. The Swiss pharmaceutical giant made good on that commitment Tuesday, leading a $100 million investment. Besides Novartis, the Series C round of funding adds so-called crossover investors, firms that invest … Continue reading “Novartis Leads $100M Round for Fibrosis-Focused Pliant Therapeutics”
Xilio Unveils New Name, $100M to Bring Targeted Cancer Drugs to Clinic
Cancer immunotherapy’s use can be limited by its side effects throughout the body. Xilio Therapeutics is developing technology that selectively activates a therapy’s potent cancer-killing activity specifically at the tumor and it has raised $100.5 million to advance two programs to clinical testing. The financing was led by Takeda Ventures. Along with the new cash, … Continue reading “Xilio Unveils New Name, $100M to Bring Targeted Cancer Drugs to Clinic”
Biogen, Sangamo Ink Neuro Deal for New “Gene Regulation” Therapies
Biogen is opening up its checkbook again to get its hands on innovative approaches to some brain disorders that have proven especially recalcitrant to new types of treatment. The Cambridge, MA-based neuroscience drug developer is paying gene editing company Sangamo Therapeutics (NASDAQ: [[ticker:SGMO]]) $350 million up front in a collaboration on potential one-time treatments for … Continue reading “Biogen, Sangamo Ink Neuro Deal for New “Gene Regulation” Therapies”
Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More
Clinical trials have historically hewn to a rigid format. A trial is designed, conducted according to that design, and then results are analyzed. Making changes in the midst of the study was a no-no. In recent years, regulators have showed openness to clinical trial designs intended to make drug testing more efficient. We’ll get to … Continue reading “Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More”
Biohaven’s Migraine Pill Is the Latest CGRP Drug to Win the FDA’s OK
[Updated 2/28/2020, 2:45 p.m. See below.] A Biohaven Pharmaceutical migraine drug has won FDA approval, clearing the way to the market for a new treatment option for the millions of people who suffer from the debilitating condition. The Biohaven (NYSE: [[ticker:BHVN]]) drug rimegepant (Nurtec) was developed for acute migraine in adults, treating a migraine attack … Continue reading “Biohaven’s Migraine Pill Is the Latest CGRP Drug to Win the FDA’s OK”
XenoTherapeutics Names Michael Yaremchuk as Its Chief Medical Officer
XenoTherapeutics on Wednesday named its first chief medical officer, Michael Yaremchuk. Boston-based XenoTherapeutics is working to advance what’s known as xenotransplantation, or the process of grafting or transplanting organs or tissues between members of different species. Its first product to enter the clinic, Xeno-Skin, is genetically engineered pig skin intended to temporarily close human burn … Continue reading “XenoTherapeutics Names Michael Yaremchuk as Its Chief Medical Officer”
Gilead, Moderna Candidates Ramp Up Coronavirus Drug, Vaccine Testing
An investigational antiviral drug Gilead Sciences has been developing to treat infections caused by the Ebola virus will be tested in about 1,000 adults diagnosed with COVID-19, the novel coronavirus that has infected tens of thousands of people and killed more than 2,500. On Wednesday, Foster City, CA-based Gilead (NASDAQ: [[ticker:GILD]]) announced the start of … Continue reading “Gilead, Moderna Candidates Ramp Up Coronavirus Drug, Vaccine Testing”
Takeda Bases PvP Biologics Buyout on Promising Early Celiac Drug Data
About three years ago fledgling San Diego-based startup PvP Biologics announced a $35 million deal with Takeda Pharmaceutical that gave the Japan pharma giant rights to acquire the company down the line. That day is here. Takeda (NYSE: [[ticker:TAK]]) acquired the company for an undisclosed amount up front, plus up to $330 million in payments … Continue reading “Takeda Bases PvP Biologics Buyout on Promising Early Celiac Drug Data”
Skyhawk’s Terry Connolly Takes On New Role as Chief Operating Officer
Skyhawk Therapeutics has appointed Terry Connolly to serve as its chief operating officer. He had spent the past year as the Waltham, MA, company’s chief business officer. Before joining Skyhawk, Connolly held multiple roles at Celgene. Skyhawk is developing small molecule drugs that correct errors in RNA splicing. The company’s preclinical pipeline includes one program … Continue reading “Skyhawk’s Terry Connolly Takes On New Role as Chief Operating Officer”
Bicycle Therapeutics Lands $30M From Genentech in New Cancer R&D Pact
Genentech is the latest company to enter a drug discovery partnership with Bicycle Therapeutics, adding a new alliance in cancer research for the clinical-stage biotech. Under an agreement announced Tuesday, Roche subsidiary Genentech is paying Bicycle (NASDAQ: [[ticker:BCYC]]) $30 million up front. As programs progress, Bicycle could earn up to $1.7 billion in total milestone … Continue reading “Bicycle Therapeutics Lands $30M From Genentech in New Cancer R&D Pact”
Invetx Fetches $15M to Develop Biologic Drugs for Man’s Best Friend
Veterinarians have a saying that a cat is not a small dog, says Invetx CEO Juergen Horn. Obviously, a dog of any size isn’t the same as a human. But Horn, a veterinarian, says there are enough similarities between the species to take the science behind biological drugs for people and apply it to animals. … Continue reading “Invetx Fetches $15M to Develop Biologic Drugs for Man’s Best Friend”
Lundbeck’s Alder Bio Bet Pays Off With FDA Approval of Migraine Drug
A migraine drug that Lundbeck added to its pipeline via its nearly $2 billion acquisition of Alder BioPharmaceuticals won FDA approval on Friday. The drug, eptinezumab (Vyepti), is part of a new class of antibody therapies developed to prevent migraine attacks before they start. These drugs block calcitonin gene-related peptide (CGRP), a protein associated with … Continue reading “Lundbeck’s Alder Bio Bet Pays Off With FDA Approval of Migraine Drug”
Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce’s $88M & More
The price of insulin, a life-saving treatment discovered a century ago, has been a flashpoint amid the broader drug pricing debate. The FDA is trying to tame high insulin prices by encouraging price competition. The FDA has historically regarded insulin as a drug. But insulin isn’t a chemical drug, it’s made from biological material. Under … Continue reading “Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce’s $88M & More”
EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device
Many companies are working to develop new drugs that target harmful proteins associated with neurodegenerative diseases. EnClear Therapies has raised a $10 million Series A round of financing from a syndicate of investors to advance a device that it says could help treat neurodegenerative diseases by filtering out such proteins from cerebral spinal fluid (CSF), … Continue reading “EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device”
Xcelerating Life Sciences Boston Will Explore Biopharma’s Future in Digital Health
Join Xconomy on April 29 at Takeda Pharmaceuticals’ Boston location for the next in our Xcelerating Life Sciences event series: Biopharma’s Future in Digital Health. The half-day conference will bring together innovators, executives, rising pioneers, entrepreneurs, investors, and scientists to examine what’s fueling Boston’s biotech investment and partnership opportunities. As the nation’s largest biopharma cluster, … Continue reading “Xcelerating Life Sciences Boston Will Explore Biopharma’s Future in Digital Health”
ResTORbio Pins “Strategic Alternatives” Pitch to Parkinson’s Promise
Three months after resTORbio’s lead drug failed a pivotal test treating lung infections in the elderly, the company is now looking for someone to buy the firm or strike a deal for its technology. In a corporate update issued Wednesday, resTORbio (NASDAQ: [[ticker:TORC]]) says it has started a process to evaluate “partnerships, acquisitions, mergers, and … Continue reading “ResTORbio Pins “Strategic Alternatives” Pitch to Parkinson’s Promise”
Xcelerating Life Sciences Boston (interactive online event)
Stay at the forefront of Boston’s technology and digital health advancements as biopharma, investment, and government come together to drive life sciences As the nation’s largest biopharma cluster, Boston has a proven track record of life science leadership, including emerging therapeutics. Digital technologies will play a critical role in the expansion of this industry poised … Continue reading “Xcelerating Life Sciences Boston (interactive online event)”
Imara Reveals IPO Plan as Sickle Cell Drug Advances in the Clinic
Sickle cell disease research is seeing a flurry of activity with several companies currently testing therapies for the genetic blood disorder and one company recently receiving FDA approval. Imara aims to set itself apart from the pack and it is preparing to go public to support continued clinical development of its own sickle cell drug. … Continue reading “Imara Reveals IPO Plan as Sickle Cell Drug Advances in the Clinic”
Voyager Therapeutics Chief Operating Officer Matthew Ottmer Resigns
Gene therapy developer Voyager Therapeutics (NASDAQ: [[ticker:VYGR]]) has lost its chief operating officer. Matthew Ottmer, who held the role since September 2017, resigned effective Feb. 12, according to a Friday securities filing. No reason was given. Though Ottmer has stepped down from his executive role, he will remain an at-will employee of Cambridge, MA-based Voyager … Continue reading “Voyager Therapeutics Chief Operating Officer Matthew Ottmer Resigns”
Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More
Drugs typically go through three phases of clinical testing to support an application for FDA approval. It’s easy to overlook Phase 4, which takes place after a drug reaches the market. Post-marketing studies aim to identify side effects not observed in the first three phases of testing. They also evaluate how a therapy works over … Continue reading “Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More”
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
Eisai is withdrawing weight-loss drug lorcaserin after a post-marketing study found a higher incidence of cancer in patients who took the medicine. The FDA said Thursday that its request for removal of the product from the market is voluntary, but Eisai has already started the process for doing so. The withdrawal follows an FDA alert … Continue reading “Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks”
Anika Therapeutics Appoints Cheryl Blanchard Interim CEO
Anika Therapeutics (NASDAQ: [[ticker:ANIK]]) board member Cheryl Blanchard has been named interim CEO of the company. Her appointment comes two weeks after the death of CEO Joseph Darling. With Blanchard stepping into her new role, the interim “Office of the President” that was created to take on Darling’s duties has been dissolved. Blanchard has been … Continue reading “Anika Therapeutics Appoints Cheryl Blanchard Interim CEO”
Palleon Pharma Promotes Li Peng to Chief Scientific Officer
Li Peng is taking on a new role at Palleon Pharmaceuticals as the company’s first chief scientific officer. Peng was previously Palleon’s vice president of research and early product development. Before joining the company, Peng held various roles at AstraZeneca (NYSE: [[ticker:AZN]]). Palleon is developing drugs that target the Siglec-Sialoglycan axis, a mechanism of immune … Continue reading “Palleon Pharma Promotes Li Peng to Chief Scientific Officer”
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
The RAS family of proteins is one of the hottest targets in cancer research despite being one of the hardest for drug hunters to hit. Revolution Medicines has raised $238 million in an IPO to finance development of therapies that it says can drug these molecules in a novel way. On Wednesday evening, Revolution priced … Continue reading “Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer”
Lyndra Taps Pacira’s Richard Stanton for Chief Medical Officer Role
Richard Stanton has joined Lyndra Therapeutics as chief medical officer, the same role he held most recently at Pacira Pharmaceuticals. Lyndra is developing drug delivery technology that turns daily medications into extended-release formulations via a mechanism that keeps a drug in the stomach longer. Last year, the Watertown, MA-based company raised $55 million in Series … Continue reading “Lyndra Taps Pacira’s Richard Stanton for Chief Medical Officer Role”
Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened.
Pfizer and Merck are each cutting ties with a smaller clinical-stage biotech after experimental drugs being developed under separate alliances fell short in human testing. Pfizer (NYSE: [[ticker:PFE]]) is walking away from a partnership with GlycoMimetics (NASDAQ: [[ticker:GLYC]]) a Rockville, MD-based company developing drugs for diseases where carbohydrates play a role. In 2011, Pfizer paid … Continue reading “Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened.”
FDA Clinical Hold Stops LogicBio’s Gene Editing Study Before It Starts
The FDA has placed a clinical hold on a LogicBio Therapeutics application to begin human testing of its experimental gene-editing therapy for a rare, inherited liver disorder. LogicBio (NASDAQ: [[ticker:LOGC]]) disclosed the clinical hold for its gene-editing therapy, LB-001, after Monday’s market close. The Cambridge, MA-based biotech said that the hold concerns “certain clinical and … Continue reading “FDA Clinical Hold Stops LogicBio’s Gene Editing Study Before It Starts”
Wave Life Sciences’ Stumble in Duchenne Leads to 22% Staff Layoff
Wave Life Sciences is cutting about 22 percent of its staff as part of a corporate shakeup that follows the company’s decision to stop work on its Duchenne muscular dystrophy programs. Singapore-based Wave (NASDAQ: [[ticker:WVE]]), which has its US operations in Cambridge, MA, said in a Feb. 6 regulatory filing it expects to have notified … Continue reading “Wave Life Sciences’ Stumble in Duchenne Leads to 22% Staff Layoff”
Eli Lilly, Roche Drugs Fail to Move Needle in Genetically Driven Alzheimer’s
Two experimental drugs from Eli Lilly and Roche have failed a clinical trial testing them as treatments for a form of Alzheimer’s disease caused by certain genetic mutations, the companies reported Monday. The study, sponsored by Washington University, tested the drugs in patients who have an early onset, inherited form of Alzheimer’s called autosomal dominant. … Continue reading “Eli Lilly, Roche Drugs Fail to Move Needle in Genetically Driven Alzheimer’s”
Takeda’s Peng Lu Joins Pharvaris as Chief Medical Officer
Pharvaris has appointed Peng Lu to serve in the newly created position of chief medical officer. Lu joins the Leiden, Netherlands-based drug developer from Takeda Pharmaceutical (NYSE: [[ticker:TAK]]), where she was vice president and global program lead for rare diseases. Lu will be based in Pharvaris’s Boston office. The company’s lead drug candidate, PHA121, is … Continue reading “Takeda’s Peng Lu Joins Pharvaris as Chief Medical Officer”
Bio Roundup: POTUS on Prices, a16z’s Fund, Aimmune’s Approval & More
The president’s State of the Union address was wide-ranging, as they tend to be, but those who tuned in heard mention of two hot health policy topics: price transparency and drug pricing reform. President Trump asserted that an executive order he signed last year directing various federal agencies to come up with new rules requiring … Continue reading “Bio Roundup: POTUS on Prices, a16z’s Fund, Aimmune’s Approval & More”
Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered
Gene editing biotech Beam Therapeutics raised $180 million in its initial public offering Wednesday after offering 48 percent more shares than it initially anticipated. Beam, which was slated to begin trading Thursday on the Nasdaq exchange under the stock symbol “BEAM,” sold 9.25 million shares, up from the 6.25 million it said it planned to … Continue reading “Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered”
Merck Charts an R&D-Focused Course Starting With a $6.5B Spinoff
Merck is corralling products representing $6.5 billion in sales and spinning them off into a separate company, a strategic bet that focusing the remaining business on developing innovative new medicines will drive future growth. The new company will take Merck’s women’s health business, older medicines that have lost patent protection, and biosimilars—drugs that are close … Continue reading “Merck Charts an R&D-Focused Course Starting With a $6.5B Spinoff”
Amylyx Pharmaceuticals Names Jeffrey Trigilio Chief Financial Officer
Amylyx Pharmaceuticals has appointed Jeffrey Trigilio to serve as its first chief financial officer. Trigilio was most recently vice president of finance at cell therapy company BlueRock Therapeutics. His previous experience includes time at Alexion Pharmaceuticals (NASDAQ: [[ticker:ALXN]]). Amylyx, which is based in Cambridge, MA, is developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s … Continue reading “Amylyx Pharmaceuticals Names Jeffrey Trigilio Chief Financial Officer”
Boston Pharmaceuticals Picks NIBR’s Basson for Chief Medical Officer
Boston Pharmaceuticals has appointed Craig Basson to serve as its chief medical officer. He joins the Cambridge, MA, company from the Novartis Institutes for Biomedical Research (NIBR), where he was global head of translational medicine for the cardiovascular and metabolic therapeutic areas. Before joining Novartis, Basson was a professor of cardiology and internal medicine at … Continue reading “Boston Pharmaceuticals Picks NIBR’s Basson for Chief Medical Officer”
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
An Aimmune Therapeutics drug developed to treat peanut allergy won FDA approval late Friday—the first time the agency has approved an oral immunotherapy for a food allergy. The Aimmune (NASDAQ: [[ticker:AIMT]]) drug, Palforzia, was developed to desensitize patients to peanuts. The FDA decision covers patients between the ages of 4 and 17 who have a … Continue reading “Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy”
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
If this week is any indication, the steady march of life science companies to Wall Street will continue in 2020. Black Diamond Therapeutics is leading the way, having raised $201 million from its IPO. In its first day of trading, the cancer drug developer watched its shares soar more than 108 percent. Black Diamond’s stock … Continue reading “Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More”
Moderna Adds Takeda’s Melanie Ivarsson as Chief Development Officer
Moderna (NASDAQ: [[ticker:RNA]]) named Melanie Ivarsson as its chief development officer. Ivarsson was most recently vice president, head of clinical operations at Takeda Pharmaceuticals (NYSE: [[ticker:TAK]]). Her previous experience includes serving as senior director, head of clinical strategy and operations at Pfizer (NYSE: [[ticker:PFE]]), and roles within the early clinical development group at Eli Lilly (NYSE: … Continue reading “Moderna Adds Takeda’s Melanie Ivarsson as Chief Development Officer”